# N. Lynn Henry

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/n-lynn-henry/

## Facts

| Field | Value |
| --- | --- |
| Citations | 12,477 |
| Field | Estrogen and related hormone effects |
| h-index | 50 |
| i10-index | 123 |
| Last Known Institution | University of Michigan |
| OpenAlex ID | https://openalex.org/A5063192858 |
| ORCID iD | 0000-0002-4771-5930 |
| Works | 401 |

## Researcher papers

- [Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group](https://scholariq.org/papers/assessment-of-ki67-in-breast-cancer-recommendations-from-the-international-ki67/)
- [American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline](https://scholariq.org/papers/american-cancer-society-american-society-of-clinical-oncology-breast-cancer/)
- [Cancer biomarkers](https://scholariq.org/papers/cancer-biomarkers/)
- [American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline](https://scholariq.org/papers/american-cancer-society-american-society-of-clinical-oncology-breast-cancer-2/)
- [Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update](https://scholariq.org/papers/breast-cancer-follow-up-and-management-after-primary-treatment-american-society/)
- [Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib](https://scholariq.org/papers/molecular-heterogeneity-and-response-to-neoadjuvant-human-epidermal-growth/)
- [Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer](https://scholariq.org/papers/predictors-of-aromatase-inhibitor-discontinuation-as-a-result-of-treatment/)
- [Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer](https://scholariq.org/papers/effect-of-acupuncture-vs-sham-acupuncture-or-waitlist-control-on-joint-pain/)
- [Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors](https://scholariq.org/papers/prospective-characterization-of-musculoskeletal-symptoms-in-early-stage-breast/)
- [Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx](https://scholariq.org/papers/use-of-biomarkers-to-guide-decisions-on-adjuvant-systemic-therapy-for-women-with/)
- [Identifying Adolescent and Young Adults’ Preferences for Oncology Symptom Management Clinical Trial Participation](https://scholariq.org/papers/identifying-adolescent-and-young-adults-preferences-for-oncology-symptom/)

## Researcher topics

- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer survivorship and care](https://scholariq.org/topics/cancer-survivorship-and-care/)

## Researcher university

- [University of Michigan](https://scholariq.org/institutions/university-of-michigan/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.